The Medical Advisor

OneDayMD Evidence Review Original publication: 2025   |   Major revisions: January, March, May and August 2026   |   Article type: Narrative evidence review / translational oncology update Abstract Cancer treatment is increasingly moving from a one-size-fits-all model toward biologically stratified combination therapy. Modern oncology can now target specific molecular alterations, activate antitumor immunity, manipulate cellular metabolism and, potentially, modify the gut microbiome. This review integrates four related areas of research: targeted therapy, immunotherapy, metabolic oncology and drug repurposing , with particular attention to the emerging role of Akkermansia and the gut microbiome. Targeted therapies provide the clearest example of precision oncology. In EGFR-mutated non-small-cell lung cancer (NSCLC), osimertinib (Tagrisso) is an established EGFR tyrosine-kinase inhibitor for appropriately selected patients. FDA labeling includes fi...

Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated:   August  2026 Contents: Introduction Lymphoma Case Series (30 case reports) Leukemia Case Series (14 case reports) Discussion Conclusion Important Disclaimers:  This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions. Ivermectin and mebendazole are used off-label as complementary therapies and are not intended to replace conventional, evidence-based cancer treatments such as chemotherapy, radiotherapy, immunotherapy, targeted therapy, or hormone therapy. Any off-label use should be discussed with and supervised by a quali...